Introduction
============

The design and development of agents that act on specific molecular and cellular targets are considered as a rational approach to control cancer. This strategy for control of cancer is based on the presumption that because cancer develops through a multi-step process, each step may be a prospective target for reversing or suppressing the process. There are a number of limitations on drug targeting technology, but, at present, the more difficult limitations are imposed by tumors themselves and by the host's response to a tumor. Moreover, successes in vitro are disputable without corresponding data in the more composite organism level.

Bladder cancer is one of the most common cancers, being the 4th most common malignancy in men and the 13th most common malignant cancer in women in the United States ([@b74-btt-1-393]). In 2007, it is estimated that 67,160 new cases of bladder cancer will be diagnosed, and 13,750 deaths will be attributed to this disease ([@b74-btt-1-393]). The incidence is higher in males (with a ratio of 3:1) and in the elderly ([@b74-btt-1-393]). Urothelial carcinoma (UC) (previously designated as transitional carcinoma or TCC) accounts for approximately 95% of bladder malignancies ([@b5-btt-1-393]).

Despite undergoing surgery with curative intent, a large proportion of patients with UC will develop metastatic disease while others will have metastases at the time of initial presentation ([@b17-btt-1-393]). Accurate clinical staging of bladder cancer remains difficult and inaccurate, with pathologic upstaging after radical cystectomy commonly demonstrated for clinically localized tumors ([@b45-btt-1-393]). Recent studies have demonstrated that combination therapy with neoadjuvant chemotherapy followed by radical surgery for muscle-invasive diseases offers a small but definite survival advantage ([@b60-btt-1-393]; [@b172-btt-1-393]). Once metastatic, however, the relative 5-years survival rate is 6%, whereas the overall 5-years survival for all stages is 82% ([@b109-btt-1-393]). For patients with muscle-invasive disease, the most common pattern of metastasis is to regional lymph nodes, but distant spread to lungs, liver, skin and bone is also typical ([@b133-btt-1-393]). Metastases to abdominal viscera, brain, and meninges are seen less frequently.

Sites of metastatic involvement correlate with response rate and survival and are important predictors of treatment outcome ([@b125-btt-1-393]). Patients with lymph node, lung, and soft-tissue metastases have better survival than those with metastases to bone and liver ([@b55-btt-1-393]; [@b94-btt-1-393]). Biopsies of distant metastatic sites are often consistent histologically with UC pattern. However, a significant disparity within these metastatic lesions with respect to growth parameters, ploidy, karyotype, oncogene expression, tumor markers, grade, and histologic features has been demonstrated ([@b133-btt-1-393]; [@b55-btt-1-393]; [@b94-btt-1-393]).

Patients with metastatic UC are usually treated with systemic chemotherapy ([@b167-btt-1-393]; [@b55-btt-1-393]; [@b121-btt-1-393]; [@b17-btt-1-393]). For more than two decades, the standard treatment has been combination therapy with methotrexate, vinblastine, adriamycin and cisplatin (MVAC). This regimen is consistently reported to produce a median survival in the range of 13--15 months ([@b167-btt-1-393]; [@b17-btt-1-393]). MVAC has significant toxicity, however, primarily neutropenia, neutropenic fever and severe mucositis, which limits its use in the predominantly older bladder cancer population. Combination therapy with gemcitabine and cisplatin (GC) has shown similar efficacy as MVAC, with less toxicity and a much lower toxic death rate (1% vs 3% for MVAC), leading to widespread substitution of GC for MVAC in clinical practice ([@b177-btt-1-393]). In the search for regimens more active than MVAC, regimens based on gemcitabine, ifosfamide, and/or paclitaxel have attracted considerable interest ([@b138-btt-1-393]; [@b7-btt-1-393]; [@b135-btt-1-393]; [@b173-btt-1-393]), but until now no substantial improvement in survival has been observed. Most of these treatments are based on the pathologic staging of tumors and do not take molecular profiles into consideration. These facts highlight the limited effectiveness of the current therapeutic regimens and that novel treatment strategies are urgently required. Novel targeted therapies hold promise to improve the current results of metastatic bladder cancer treatment. Several trials are ongoing evaluating these new agents alone or in combination with chemotherapy. The integration of these newer biologic agents should be a primary direction of research with the objective to interfere with multiple aspects of bladder cancer progression.

Molecular events in metastatic bladder cancer
=============================================

The identification of mutated genes and gene products which are aberrantly expressed in invasive and metastatic bladder tumors permits the design of molecularly targeted therapies. There have been recent major developments in our understanding of the molecular phenotype of bladder cancers ([Table 1](#t1-btt-1-393){ref-type="table"}) ([@b37-btt-1-393]; [@b82-btt-1-393]; [@b32-btt-1-393]; [@b5-btt-1-393]; [@b2-btt-1-393]). Over the last two decades, scientists have demonstrated that two distinct molecular pathways are involved in the genesis of UC based on histopathology and clinical behavior ([Figure 1](#f1-btt-1-393){ref-type="fig"}) ([@b183-btt-1-393]; [@b5-btt-1-393]): superficial papillary and invasive non-papillary bladder tumors.

Papillary carcinoma, which account for more than 80% of bladder tumors, has a tendency to recur locally (approximately 70%), but rarely invades and metastasizes. On the other hand, most invasive bladder tumors have no known papillary precursor, are solid invasive lesions, are commonly associated with carcinoma in situ (CIS) and have a much less favorable prognosis. Genetic analyses have shown that CIS exhibits a spectrum of genetic alterations (such as *TP53* mutation and loss of heterozygosity -LOH- at 3p, 8p, 13q, and 17p) similar to that seen in invasive UC and very distinct from that seen in low grade papillary UC, where only LOH at chromosome 9 is common ([@b183-btt-1-393]).

In invasive and metastatic bladder cancers, among the different oncogenes and tumor suppressor genes (TSG) which have been studied ([Table 1](#t1-btt-1-393){ref-type="table"}), particular interest has been focused on defects in pathways controlling the G1/S cell cycle checkpoint (involving the tumor suppressor genes *TP53* and *RB1*), angiogenesis, DNA methylation, multidrugs resistant genes and on activation of the Ras-MAPK signal transduction pathway, in which associations between molecular abnormalities and tumor prognosis have been identified ([@b82-btt-1-393]).

Cell cycle regulators
---------------------

A prerequisite for normal cell proliferation is an orderly progression through the cell cycle, which is predominately controlled by protein complexes that are composed of cyclins and cyclin-dependent kinases (CDK). These complexes control progression through the cell cycle by phosphorylating key proteins that are involved in cell cycle transition points. The fundamental and best studied genes involved in cell cycle regulation are the tumor suppressor genes *RB1*, *TP53, CDKN2A (P16/INK4A-ARF)* and *CDKN1A* (*P21WAF1/Cip1)* and the oncogene *MDM2*.

The p53 protein is a central molecule in several important cellular programs related to cancer development, progression and response to therapy, as apoptosis and DNA repair ([@b33-btt-1-393]). It inhibits cell cycle progression at G1-S transition and mediates its control through the transcriptional activation of *CDKN1A. TP53* mutations are the most common genetic defect in human tumors ([@b67-btt-1-393]) and most studies on *TP53* have used immunohistochemical detection of the p53 protein as a surrogate for gene inactivation by mutation. Mutant p53 has an increased half life and can be easily detected, whereas normal physiological concentrations of the wild-type protein are undetectable. The mutations are generally missense point mutations, which result in altered proteins that are resistant to normal regulatory degradation by the ubiquitin pathway ([@b39-btt-1-393]). In bladder cancer, mutation of p53 is a feature of more advanced, poorly differentiated tumors and appears to be associated with a high risk of metastatic recurrence and a poor prognosis ([@b43-btt-1-393]; [@b92-btt-1-393]; [@b142-btt-1-393], [@b141-btt-1-393]; [@b163-btt-1-393]; [@b42-btt-1-393]; [@b129-btt-1-393]; [@b130-btt-1-393]). *TP53* has been evaluated in bladder cancer in order to predict and to be correlated with an increased chemosensitivity ([@b99-btt-1-393]; [@b166-btt-1-393]). Adjuvant chemotherapy was associated with a decreased risk of recurrence and improvement in survival when given to patients with *TP53*-altered tumors ([@b33-btt-1-393]). In a transfected bladder cell line, the re-expression of a wild-type p53 protein suppressed the cytotoxic effects of paclitaxel and gemcitabine ([@b78-btt-1-393]). Paclitaxel was shown to require functionally mutated *TP53* to induce cell death, indicating that it may be more effective against UC with *TP53* mutations, while gemcitabine was effective regardless of p53 protein function. Induction of *TP53* gene expression has been shown to be facilitated by prior exposure to cytotoxic agents such as cisplatin and mitomycin C ([@b125-btt-1-393]). This altered expression of *TP53* may correlate with increased resistance to combination chemotherapy protocols (ie, MVAC) ([@b33-btt-1-393]; [@b141-btt-1-393]) and may be associated with previous intravesicular treatment ([@b7-btt-1-393]). All these findings may provide a rationale for selecting chemotherapy on the basis of the *TP53* status.

However, not all bladder tumors with *TP53* alterations progress or recur ([@b43-btt-1-393]; [@b44-btt-1-393]). As previously described, the action of wild type *TP53* on cell cycle regulation is mediated, in part, through up-regulation of *CDKN1A* (*P21/WAF1)*. p21 protein, a CDK inhibitor, binds and inhibits cdk2, a protein that is necessary for transition into the next phase of the cell cycle. Alterations of *TP53* result in loss of p21 expression, which leads to unregulated cell growth. However, it has been shown that p21 expression can also be regulated through p53-independent pathways which may maintain p21 expression despite the presence of altered p53 ([@b81-btt-1-393]). Thus, from a theoretical point of view, p21 protein detection should provide additional information to p53 positivity alone. In bladder cancer, the loss of p21 expression can be a significant and independent predictor of UC progression, whereas the maintenance of p21 expression appears to abrogate the deleterious effects of *TP53* alterations ([@b165-btt-1-393]). In multivariate analysis, p21 labeling was an independent predictor of tumor recurrence and of survival ([@b166-btt-1-393]). Patients with *TP53*-altered/p21-negative tumors demonstrated a higher rate of recurrence and worse survival compared with those with *TP53*-altered/p21-positive tumors ([@b108-btt-1-393]; [@b165-btt-1-393]).

*MDM2* is another gene correlated with *TP*53 expression. In normal cells, *MDM2* regulates *TP*53 function by marking p53 protein for degradation via ubiquitin conjugation and inactivating p53 by binding to its transactivation domain ([@b119-btt-1-393]; [@b182-btt-1-393]). Increased p53 levels transactivate the *MDM2* promoter causing its upregulation. Amplification of *MDM2* results in the escape from *TP53*-regulated growth control. Nevertheless, the role of *MDM2* in regulating p53 protein levels in UC remains unclear. It is generally agreed that Mdm2 over-expression itself provides no independent prognostic information over clinico-pathological parameters ([@b145-btt-1-393]; [@b154-btt-1-393]; [@b169-btt-1-393]). However, the combination of *MDM2* and *TP53* status could determine a higher prognostic power on progression ([@b145-btt-1-393]; [@b154-btt-1-393]) and survival ([@b154-btt-1-393]) in bladder cancer patients.

The *RB1* gene was the first tumor suppressor gene identified ([@b51-btt-1-393]). In its physiologic active form the nuclear phosphoprotein Rb1 encoded protein inhibits cell cycle progression at the G1 to S checkpoint by binding to a number of cellular proteins including the transcription factor E2F ([@b21-btt-1-393]). The inactivation of *RB1* has been described as an important step in carcinogenesis and progression of various tumors ([@b6-btt-1-393]; [@b57-btt-1-393]). The comparison of immunohistochemical Rb1 expression and molecular analysis in primary UCs showed that *RB1* alterations (observed in the 19%--29.4% of the tumors) are more frequently seen in muscle-invasive and high-grade tumors ([@b30-btt-1-393]; [@b31-btt-1-393]; [@b184-btt-1-393]), and that in patients with muscle-invasive bladder cancer the 5-year survival was significantly decreased in cases with altered Rb1 protein ([@b30-btt-1-393]; [@b95-btt-1-393]; [@b52-btt-1-393]).

Important in the regulation of the cell cycle is also the *CDKN2A* gene (also known as *P16, INK4A, MTS1, CDKN2A*), which is a well-characterized CDK inhibitor ([@b93-btt-1-393]). This protein functions upstream of Rb1 to block cyclin-D directed phosphorylation of Rb1, thus inducing G1 arrest. *CDKN2A* mutations and homozygous deletions have been detected in the 3.1% and 14.1% of bladder cancers analyzed, respectively ([@b120-btt-1-393]). Furthermore, *CDKN2A* is thought to be susceptible to transcriptional silencing by promoter methylation, which affects from 14.9% to 26.5% of the tumors tested ([@b120-btt-1-393]; [@b20-btt-1-393]). Inactivation of *CDKN2A* by any of the mechanisms will lead to affect both p16 and p19ARF proteins, and subsequently disrupting the Rb1 and p53 pathways ([@b120-btt-1-393]).

The interaction of p53 and p21 proteins in cell cycle regulation, and the data looking at the cooperative effects of p53 and Rb1 ([@b31-btt-1-393]), provide good examples of the increasing evidence that mutation in a single TSG is unlikely to be the only factor resulting in carcinogenesis. Several studies have conducted multivariate analyses using various combinations of cell cycle regulators markers (*TP53*, *CDKN1A*, *RB1*, *CDKN2A*, *MDM2*) to generate prognostic panels ([@b96-btt-1-393]; [@b151-btt-1-393]; [@b152-btt-1-393]). [@b96-btt-1-393] and [@b151-btt-1-393] found that the 12.1% of the 140 tumor analyzed, had an altered p53 pathway, defined by the detection of mutant *TP53* and/or p53 nuclear overexpression, loss of p21 nuclear expression, and Mdm2 nuclear overexpression. Moreover, they exhibited the worst clinical outcome in the observation period. Shariat et al ([@b152-btt-1-393]), found that the 83% of 80 bladder cancers had at least one marker altered (p53, p21, and pRB or p16), and 21 patients (26%) had all three altered. These studies demonstrated a biological and pathological relationship between these markers spanning multiple molecular pathways and progression, suggesting their important role in bladder carcinogenesis and their rational target for the design of molecularly targeted therapies.

Tumor angiogenesis
------------------

Angiogenesis is not only important in maintaining the supply of oxygen and nutrients to the proliferating tumor cells and to the metastatization of the primary tumor, but also for the survival and spreading of secondary localizations. The most important factor affecting this process is the pro-angiogenic vascular endothelial growth factor (VEGF). High serum VEGF levels and VEGF IHC expression have been associated with high UC stage and grade, vascular invasion, CIS, metastases and poor disease free survival ([@b10-btt-1-393]; [@b189-btt-1-393]). Moreover, VEGF levels affect the production of interleukin-8 (IL-8) and matrix metalloproteinases (MMPs) ([@b118-btt-1-393]), which enhances angiogenesis of the tumor, and migration and invasion of bladder cancer cells. Increased expression of MMP-9, IL-8 and VEGF has been proven to be correlate with stage and outcome of advanced bladder tumors ([@b11-btt-1-393]).

DNA methylation
---------------

The promoter methylation has been demonstrated to be a frequent mechanism of inhibition for important genes including those that influence the cell cycle and signal transduction in cancer ([@b20-btt-1-393]). In UC, the role of this epigenetic event in the silencing of TSGs is still under study. The promoter region of *TP53* gene is almost never methylated in muscle-invasive UC ([@b86-btt-1-393]), whereas, as mentioned above, *CDKN2A* is susceptible to transcriptional silencing by promoter methylation ([@b120-btt-1-393]; [@b20-btt-1-393]). Recently, additional findings are confirming the importance of this mechanism in the process of bladder metastatization ([@b116-btt-1-393]). Further studies should elucidate the significance of hyper-methylation and the role of demethylating agents in the treatment of locally advanced and metastatic UCs ([@b32-btt-1-393]).

Multidrug resistant genes
-------------------------

The tumor resistance to chemotherapy is the major problem affecting the management of metastatic and aggressive bladder cancers. Over-expression of the *MDR1* gene leads to drug resistance via up-regulation of a membrane-bound 190 kDa phosphoglycoprotein, that serves as an energy-dependent drug flux pump and eliminates toxic metabolites out of the cells ([@b62-btt-1-393]). The expression of this protein correlated in various tumors with low local drug accumulation and increased drug resistance ([@b41-btt-1-393]), which has also been observed in bladder cancer ([@b27-btt-1-393]; [@b111-btt-1-393]; [@b127-btt-1-393]). [@b127-btt-1-393], observed a positive p-glycoprotein immunostaining in 6 of 46 untreated primary lesions (13%), while 6 of 16 (38%) post-therapy primary tumors were immunoreactive. None of the untreated metastases (0 of 17) were positive; however, 6 of 11 (55%) post-therapy specimens showed varied percentages of positivity. Of interest, the highest percentage, 50%--70% of tumor cells stained, was observed in metastatic lesions from patients who had received 6 or more chemotherapy cycles. These characteristics suggest that targeting of *MDR1* expression may improve the response of advanced and metastatic bladder tumors to systemic chemotherapy.

Growth factor receptors
-----------------------

In invasive and metastatic UC two receptor tyrosine kinases, the epidermal growth factor receptor (*EGFR*) and *ERBB-2* (also called *HER-2* or *NEU*), are over-expressed (35%--86% for *EGFR*, and 41%--52% for *ERBB-2*) and associated with poor outcome ([@b91-btt-1-393]; [@b134-btt-1-393]; [@b84-btt-1-393]; [@b69-btt-1-393])

Preclinical and clinical data strongly support the involvement of the *EGFR* in the growth and progression of human cancers ([@b115-btt-1-393]; [@b103-btt-1-393]; [@b36-btt-1-393]) as well as demonstrate a high correlation in cancer patients between receptor/ligand expression and poor prognosis ([@b115-btt-1-393]). EGFR is a transmembrane glycoprotein that is activated by the binding of epidermal growth factor (EGF) and of transforming growth factor (TGF) to its external domain. In normal cells, binding of EGF causes activation of the EGFR, leading to receptor dimerization and autophosphorylation. The activated receptor then recruits proteins that convert Ras to its activated state, which can then transduce a mitogenic signal through the Ras-MAPK pathway by activating the MAPK/ERK complex. This activation sets off several cell regulation processes such as proliferation, migration and adhesion ([@b105-btt-1-393]; [@b106-btt-1-393]; [@b137-btt-1-393]). Although the mechanism by which EGFR regulates tumor biology in bladder cancer is not clearly defined, it has been demonstrated that EGFR signaling regulates cellular proliferation, differentiation, survival, invasion; and it is implicated in the induction of tumor induced angiogenesis and metastasis ([@b104-btt-1-393]; [@b115-btt-1-393]).

Immunohistochemical studies have demonstrated that EGFR is over-expressed in human UC compared to the normal urothelium ([@b112-btt-1-393]; [@b139-btt-1-393]). Moreover, it has been observed that normally the urothelial cells which over-express EGFR are found primarily in the basal layer of the urothelium ([@b105-btt-1-393]; [@b106-btt-1-393]; [@b139-btt-1-393]), whereas, in malignant and dysplastic urothelium, EGFR is expressed in all cell layers ([@b5-btt-1-393]). Most importantly, it has also been observed that the level of EGFR expression directly correlates with tumor grade, stage, and survival ([@b113-btt-1-393]; [@b106-btt-1-393]; [@b91-btt-1-393]; [@b101-btt-1-393]; [@b23-btt-1-393]; [@b131-btt-1-393]). Patients with muscle-invasive UC which over-express EGFR have only a 20% probability of long term cancer-specific survival, which is significantly worse than the survival of those whose tumors did not express EGFR ([@b114-btt-1-393]). In metastatic bladder cancer, the majority of metastases from patients over-expresses the EGFR, and this expression is not down-regulated by chemotherapy or radiation ([@b114-btt-1-393]).

In normal and malignant cells, the preferred partner for the EGFR molecule is erbB-2, a member of the *ERBB* gene family, and encoded by the *ERBB*-*2*/*HER-2/NEU* gene. This heterodimeric formation acts as the most efficient receptor for EGF. As observed in breast, gastric and ovarian cancers, the erbB-2 protein was found to be over-expressed frequently in urinary bladder carcinoma ([@b106-btt-1-393]; [@b143-btt-1-393]; [@b137-btt-1-393]) and it has also been found associated with increasing tumor grade, poor survival and incidence of metastatic disease ([@b110-btt-1-393]; [@b143-btt-1-393]; [@b53-btt-1-393]). The prognostic power of its over-expression increases when combined with other erbB receptors (especially EGFR and erbB-3) ([@b22-btt-1-393]). Of interest, in one study ([@b75-btt-1-393]) almost 70% of erbB-2 negative primary muscle-invasive tumors had erbB-2 positive corresponding distant metastasis.

From the bench to the bedside
=============================

Advances in the understanding of the molecular biology of UC continue to contribute to the identification of molecular pathways upon which new therapeutic approaches can be designed. The goal of targeted therapy is to optimize the therapeutic ratio of an anti-neoplastic drug by maximizing its effect on tumor cells, and at the same time minimizing toxicity for normal cells. Various approaches have been developed to specifically targeting the phenotype of tumors. Such therapies involve the use of antibodies or small molecule enzyme inhibitors which interact with specifically target molecules differentially expressed between tumor and normal cells. In [Table 2](#t2-btt-1-393){ref-type="table"} the wide range of novel therapeutic agents (viral vector carrying wild-type genes, small molecule inhibitors and monoclonal antibodies) are summarized. Many of these agents are being introduced in clinical trials.

Targeting cell cycle regulators
-------------------------------

The knowledge that genetic alterations of the *TP53* gene occur in up to 70% of muscle-invasive bladder cancers ([@b82-btt-1-393]) make *TP53* gene an extremely attractive target for rationally designed therapies. Small molecules that can directly restore *TP53* function are CP-31398 ([@b49-btt-1-393]), which should restore the conformational structure and DNA-binding ability of mutant p53, and PRIMA-1 *(P53 Reactivation and Induction of Massive Apoptosis-1*), which has been shown to suppress the growth of cells expressing mutant p53 ([@b13-btt-1-393]) and to synergize with cisplatinum to induce tumor cell apoptosis ([@b14-btt-1-393]).

However, the most suitable approach to target p53 pathway, seems to be the direct delivery of wild-type *TP53* gene by viral vector in intra-vesical instillation. The first clinical trial involving intra-vesical delivery of a gene therapy vector (vaccinia virus) has been published by our group ([@b56-btt-1-393]). The vector used has been subsequently recombined with *TP53* (rVV-TK-53) in orthotopic murine animals ([@b47-btt-1-393]). Similar gene therapy trials, in which adenovirus containing *TP53* gene (AdCMV-TP53) was used, have demonstrated tumor inhibition in bladder cancer cell lines and xenograft models ([@b122-btt-1-393]). Two similar adenoviral vectors containing the *TP53* gene have been instilled into the bladder, both as single and multiple instillations, and have led to expression of functional p53 that can be detected in the bladder epithelium ([@b85-btt-1-393]; [@b122-btt-1-393]). In addiction, these trials involving intravesical instillation of the vector have revealed a high level of tolerance, increased transduction efficacy and expression when used in combination with transduction-enhancing agents ([@b85-btt-1-393]; [@b122-btt-1-393]), and a synergistic effect in combination of cisplatin leading to increased apoptosis ([@b123-btt-1-393]). [@b123-btt-1-393], observed evidence of tumor response in one of 13 advanced superficial bladder cancers treated.

Another gene therapy viral vector, which might be used in the delivery of a normal *TP53* gene in bladder cancer cells, involves the selectively replicating adenovirus dl1520 (ONYX-015) ([@b63-btt-1-393]). Deletion of the E1B 55 kDa protein gene from the viral genome results in selective replication of cells that lack a functional p53 pathway. In normal cells with functional p53, the virus cannot replicate and is therefore harmless ([@b63-btt-1-393]; [@b136-btt-1-393]). In a number of Phase I and Phase II clinical trials, the use of this viral vector has demonstrated a safety record and has been shown to be effective in combination with cisplatin, as combined-modality therapy ([@b77-btt-1-393]). In a single study, treatment caused tumors to shrink in 25 of the 30 cases evaluated ([@b77-btt-1-393]). Objective responses (decrease of 50% or more) of injected tumors were documented in 63% of patients who could be evaluated (19 of 30). There were 8 (27%) complete and 11 (36%) partial responses. ONYX-015 therefore represents an attractive agent for the treatment of the majority of high-risk TP53 mutant bladder cancers. Similarly, conditionally replicating E1a-deleted adenoviruses ([@b64-btt-1-393]) may selectively target approximately 37% of muscle-invasive bladder cancers which have shown mutations in the *RB1* tumor suppressor gene. In normal bladder cells with functional Rb1, the absence of viral E1a gene function will prevent replication of the viral genome. However, in bladder tumors with mutant Rb1, there should be no effective barrier to viral replication and as with ONYX-015 in p53-defective cells, the virus would be expected to be selectively apoptotic. Another vector carrying *RB1* is Ad-RB94, which is a replication-deficient adenoviral construct with Rb94, a protein which lacks 112 amino acid residues of the wild-type Rb1 protein (Rb110) resulting in a more potent tumor and growth suppressor than the normal protein ([@b185-btt-1-393]). This vector has been observed to be very selective to both bladder cancer *RB1*-negative and *RB1*-positive cells, inducing growth suppression and caspase-dependent apoptosis ([@b188-btt-1-393]).

Recent data proposed hyper-phosphorylation of *RB1* as mechanism for Rb1 tumor suppressor pathway inactivation in bladder cancer ([@b20-btt-1-393]). Thus, a treatment leading to hypo-phosphorylation of the wild-type *RB1* promoter using CDKIs may improve prognosis. Recently, non-specific CDKIs like flavopiridol (L86-8275) and UCN-01 (7-hydroxystaurosporine) have entered clinical trials ([@b149-btt-1-393]). Moreover, flavopiridol also decreases cyclin D1 levels, which are elevated in many UC cases ([@b148-btt-1-393]).

Targeting growth factor receptors
---------------------------------

Two of the principal targets in the signal transduction cascade in metastatic and invasive tumors are EGFR and erbB-2 proteins ([@b8-btt-1-393]; [@b9-btt-1-393]). A series of studies targeting both the EGFR and the erbB-2, which are overexpressed or amplified in bladder cancer ([@b12-btt-1-393]; [@b54-btt-1-393]; [@b75-btt-1-393]; [@b146-btt-1-393]; [@b180-btt-1-393]), are under way and will help to define the role of these new targeted therapies in the treatment of advanced UCs.

Several strategies have been designed to target these receptor tyrosine kinases ([@b102-btt-1-393]). The two most studied approaches to targeting EGFR are monoclonal antibodies against the extracellular domain of the receptor (Cetuximab/IMC-C225 \[Erbitux\]) and inhibitors of the receptor tyrosine kinase domain (Gefitinib/ZD1389 \[Iressa\], Erlotinib/OSI-774 \[Tarceva\]) ([@b35-btt-1-393]; [@b103-btt-1-393]). Trastuzumab (Herceptin), a monoclonal antibody against erbB-2, has prompted the initiation of a phase I/II clinical trial to determine the toxicity of combined chemo-radiotherapy (paclitaxel, carboplatin and gemcitabine) with or without this agent in patients with prior cystectomies for muscle invasive bladder cancer (ClinicalTrials.gov; [@b70-btt-1-393]; [@b17-btt-1-393]; [@b69-btt-1-393]). A recently introduced agent, sorafenib (BAY 43-9006 \[Nexavar\]), is a multikinase inhibitor targeting various molecules, including EGFR and erbB-2, and is currently in phase II clinical trials for advanced and metastatic UC (ClinicalTrials.gov).

Based on the success seen with anti-erb-2 monoclonal antibodies and the promising results with EGFR targeted agents in other tumor types, there is a great interest in assessing these agents in patients with bladder cancer. Inhibition of EGFR and erbB-2 pathways, either by physical receptor blockade or with small molecule inhibitors of the receptor's tyrosine kinase activity, leads to demonstrable anti-tumor effects in animal models ([@b115-btt-1-393]; [@b103-btt-1-393]; [@b65-btt-1-393]). More importantly, multiple reports confirm that EGFR directed therapy in combination with cytotoxics produces a much-enhanced biologic effect ([@b103-btt-1-393]). Blocking signaling through EGFR on tumor cell surfaces can promote apoptosis, inhibit angiogenesis and metastases, and consequently cause tumor regression ([@b72-btt-1-393]).

Gefitinib, as erlotinib, inhibits the activity of tyrosine kinase in the intracellular component of the EGFR, thus preventing receptor autophosphorylation and subsequent activation ([@b161-btt-1-393]). The combination with platinum-derived agents (cisplatin, oxaliplatin, carboplatin), taxanes (paclitaxel, docetaxel) and topoisomerase inhibitors, shows enhanced growth inhibition ([@b25-btt-1-393]). Its anti-proliferative effect in bladder cancers has been demonstrated in vitro and in vivo, and now it is in phase II clinical trials for advanced or metastatic UC (ClinicalTrials.gov; [@b38-btt-1-393]; [@b117-btt-1-393]). Erlotinib, in combination with green tea extract (Polyphenon E) is under study in a phase II clinical trial for preventing cancer recurrence in former smokers with resected UC (ClinicalTrials.gov).

Cetuximab binds to the EGFR with high affinity, blocks ligand-induced tyrosine kinase activity and stimulates receptor internalization. In vitro, proliferation of 253J B-V cells was inhibited more by the combination of cetuzimab and paclitaxel than with either cetuzimab or paclitaxel ([@b71-btt-1-393]). The combination enhanced apoptosis in tumor and endothelial cells compared with either agent alone, most likely mediated by inhibition of angiogenesis and induction of apoptosis ([@b126-btt-1-393]). The combination of cetuximab and paclitaxel has been evaluated in mice with metastatic human bladder UC with encouraging results ([@b71-btt-1-393]).

New therapeutic targets
-----------------------

One of the mechanisms used in cell transformation is the escape from the normal control mechanisms of the apoptotic process. In the attempt to predispose cancer cells to apoptosis, anti-sense oligonucleotide gene therapy directed to *BCL-2* mRNA has already been demonstrated to reverse cisplatin resistance in bladder tumor cell lines in vitro, ([@b70-btt-1-393]) and it will be interesting to see whether these results can be reproduced in pre-clinical models and in clinical trials.

Recently, the importance of VEGF and bFGF in advanced and metastatic UC has grown and a number of agents have been designed against them, many of which have already entered clinical trials. The most popular is endostatin, which decreases VEGF expression and tumor growth by inducing apoptosis ([@b40-btt-1-393]). Moreover, the lentiviral gene transfer of endostatin by intravesical instillation decreases orthotopic human bladder tumor growth ([@b79-btt-1-393]). Bevacizumab (Avastin), a monoclonal antibody against VEGF, already used for other type of cancers ([@b73-btt-1-393]), is in phase II clinical trials in combination with cisplatin and gemcitabine for metastatic UC (ClinicalTrials. gov). VEGF Trap consists in a fully humanized, soluble decoy VEGF receptor generated by fusing the extracellular domains of VEGFR-1 and VEGFR-2 to the Fc portion of human IgG1. The mechanism of action is very similar to bevacizumab, binding and inactivating VEGF. In preclinical models it inhibits tumor growth and angiogenesis ([@b80-btt-1-393]). In addition, it is in use in clinical trials against metastatic UCs (ClinicalTrials.gov).

Bortezomib (PS-341) is a dipeptidyl boronic acid inhibitor of the 20S proteasome, which also inhibits secretion of the pro-angiogenic factors matrix metalloproteinase-9, interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF) ([@b187-btt-1-393]). The effects of bortezomib on the growth of human 253JB-V bladder cancer cells showed inhibition of cell growth in a concentration-dependent fashion and higher growth inhibitory effects of gemcitabine in vitro ([@b17-btt-1-393]). These effects were associated with accumulation of p53 and p21 and suppression of cyclin-dependent kinase 2 activity. In vivo studies with 253JB-V tumors growing in nude mice demonstrated that bortezomib did not inhibit tumor growth when it was delivered as a single agent. However, the combination therapy with bortezomib plus gemcitabine produced synergistic tumor growth inhibition associated with strong suppression of tumor cell proliferation ([@b17-btt-1-393]).

The role of hyper-methylation of tumor suppressor gene promoters in UC has recently been stressed, highlighting the importance of using demethylating agents to reverse the hypermethylation in advanced and metastatic UCs ([@b34-btt-1-393]). The most used agents are nucleoside analogs such as 5-azacytidine (5-Aza-CR), 5-aza-2′-deoxycitidine (5-Aza-CdR, decitabine), and zebularine. These therapeutics have a modified cytosine ring attached to either a ribose or deoxyribose moiety, which inhibits the DNA methylation ([@b186-btt-1-393]) and they are now under study in the treatment of UC.

Apart from the herein mentioned therapeutic agents, other inhibitor classes such as anti-topoisomerase I (Irinotecan) and histone deacetylase inhibitors (vorinostat) are used at the moment in clinical trials for the treatment of advanced and metastatic UC (ClinicalTrials.gov), but further investigations are needed to clarify their role in bladder cancer treatment.

Conclusion
==========

Although bladder cancer is one of the leading tumors in western world, very little is still known about the molecular mechanisms that determine tumor formation in the bladder urothelium and the process of its metastatization. A better understanding of the molecular biology of bladder cancer will undoubtedly influence the selection of new therapeutic modalities. The value of integrating new biologically targeted agents into combined modality treatment for patients with metastatic bladder cancer has still to be proven. However, efficiently designed and rationalized trials, targeting therapeutic approaches to the molecular and histological characteristics of urothelial cancers, hold promise to improve the current results of metastatic bladder cancer treatment.
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![Proposed model for urothelial tumorigenesis and progression. Papillary tumors and carcinoma in situ (CIS) have unique molecular profiles and arise from two distinct pathways.](btt-1-393f1){#f1-btt-1-393}

###### 

Principal genes altered in urothelial bladder carcinoma

  Gene (chromosomal location)   Alteration                                  Clinical association (References)
  ----------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tumor suppressor genes**                                                
  FHIT (3p14.2)                 LOH, methylation                            Survival, muscle invasion ([@b4-btt-1-393]; [@b160-btt-1-393]; [@b175-btt-1-393])
  CDKN1A (6p21)                 Down-regulation, point mutation             Recurrence, survival, response to chemotherapy ([@b152-btt-1-393]; [@b165-btt-1-393])
  FEZ1/LZTS1 (8p22)             LOH, point mutation                         Progression ([@b174-btt-1-393])
  CDKN2A (9p21)                 LOH, methilation, point mutation            Recurrence ([@b120-btt-1-393])
  PTCH (9q22)                   LOH, point mutation                         -- ([@b98-btt-1-393])
  TSC1 (9q34)                   LOH, point mutation                         -- ([@b68-btt-1-393])
  PTEN (10q23)                  LOH, point mutation                         -- ([@b3-btt-1-393]; [@b15-btt-1-393]; [@b178-btt-1-393])
  CDKN1B (12q12)                Point mutation                              Recurrence, progression, metastatic disease, survival ([@b50-btt-1-393]; [@b76-btt-1-393]; [@b83-btt-1-393]; [@b88-btt-1-393]; [@b150-btt-1-393])
  RB1 (13q14)                   LOH, point mutation                         Progression, muscle invasion, survival ([@b16-btt-1-393]; [@b30-btt-1-393]; [@b59-btt-1-393]; [@b95-btt-1-393]; [@b184-btt-1-393])
  TP53 (17q14)                  LOH, point mutation                         Progression, muscle invasion, survival, response to chemotherapy ([@b33-btt-1-393]; [@b43-btt-1-393]; [@b92-btt-1-393]; [@b96-btt-1-393]; [@b128-btt-1-393]; [@b130-btt-1-393]; [@b142-btt-1-393], [@b141-btt-1-393]; [@b157-btt-1-393]; [@b163-btt-1-393])
  NF-1 (17q11)                  Unknown                                     -- ([@b1-btt-1-393]; [@b170-btt-1-393])
  BC10 (20q11.1-q12)            Unknown                                     Muscle invasion ([@b58-btt-1-393])
  **Oncogenes**                                                             
  FGFR3 (4p16)                  Activating mutation                         -- ([@b18-btt-1-393]; [@b156-btt-1-393])
  EGFR (7q11.2-q12)             Amplification                               Progression ([@b23-btt-1-393]; [@b91-btt-1-393]; [@b101-btt-1-393]; [@b105-btt-1-393]; [@b113-btt-1-393]; [@b134-btt-1-393]; [@b164-btt-1-393]; [@b176-btt-1-393])
  C-MYC (8q24)                  Amplification                               Progression ([@b24-btt-1-393]; [@b97-btt-1-393]; [@b140-btt-1-393])
  H-RAS (11p15.5)               Activating mutation                         Recurrence ([@b46-btt-1-393]; [@b48-btt-1-393])
  CCND1 (11q13)                 Amplification, chromosomal rearrangements   Progression ([@b132-btt-1-393]; [@b155-btt-1-393]; [@b179-btt-1-393])
  MDM2 (12q13-14)               Amplification                               Progression, survival ([@b61-btt-1-393]; [@b89-btt-1-393]; [@b145-btt-1-393]; [@b153-btt-1-393]; [@b154-btt-1-393]; [@b169-btt-1-393])
  ERBB-2 (17q21.1)              Amplification                               Metastatic disease, survival ([@b22-btt-1-393]; [@b29-btt-1-393]; [@b53-btt-1-393]; [@b75-btt-1-393]; [@b100-btt-1-393]; [@b110-btt-1-393]; [@b171-btt-1-393])
  STK15/BTAK (20q13)            Amplification                               Metastatic disease, survival ([@b147-btt-1-393])

###### 

Innovative targeted agents for metastatic bladder cancer treatment

  Target                           Agent          Mechanism of action
  -------------------------------- -------------- -----------------------------------------------------------------------------------------------------------------
  p53 mutated                      AdCMV-TP53     Delivery of functional TP53 into cells ([@b123-btt-1-393])
  p53 mutated                      rVV-TK-53      Delivery of functional TP53 into cells ([@b47-btt-1-393])
  p53 mutated                      ONYX-015       Delivery of functional TP53 into cells ([@b77-btt-1-393])
  p53 wild-type and mutated        CP-31398       Restores mutant p53; stabilizes wild-type p53 ([@b66-btt-1-393]; [@b168-btt-1-393])
  p53 mutated                      PRIMA-1        Restores transcriptional activity of mutant p53 ([@b14-btt-1-393])
  Rb-positive and negative cells   Ad-Rb94        Replaces Rb function ([@b188-btt-1-393])
  Cyclin-dependent kinases         Flavopiridol   Nonspecific cyclin-dependent kinase inhibitor ([@b149-btt-1-393])
  Cyclin-dependent kinases         UCN-01         Nonspecific cyclin-dependent kinase inhibitor ([@b149-btt-1-393])
  EGFR                             Gefitinib      Inhibition of tyrosine kinase activity ([@b25-btt-1-393])
  EGFR                             Erlotinib      Inhibition of tyrosine kinase activity ([@b90-btt-1-393]; [@b107-btt-1-393])
  EGFR                             Cetuximab      Prevents signal transduction ([@b71-btt-1-393])
  erbB2                            Trastuzumab    Inhibits HER2 and activates anti-tumor immune response ([@b69-btt-1-393]; [@b144-btt-1-393]; [@b162-btt-1-393])
  Receptor tyrosine kinase         Sorafenib      Multikinase inhibitor ([@b19-btt-1-393]; [@b87-btt-1-393]; [@b124-btt-1-393]; [@b159-btt-1-393])
  VEGF                             Endostatin     Inhibition of cell growth and migration ([@b79-btt-1-393])
  VEGF                             Bevacizumab    Binds and inactivates VEGF ([@b73-btt-1-393])
  VEGF                             VEGF Trap      Binds and inactivates VEGF ([@b80-btt-1-393])
  VEGF                             Sunitinib      Inhibition of tyrosine kinase activity ([@b158-btt-1-393])
  VEGF                             Pazopanib      Inhibition of tyrosine kinase activity (ClinicalTrials.gov)
  VEGF/EGFR                        ZD6474         Inhibition of tyrosine kinase activity ([@b26-btt-1-393])
  Hypermethylated TSG promoters    5-Aza-CR       DNA incorporated ([@b109-btt-1-393])
  Hypermethylated TSG promoters    5-Aza-CdR      DNA incorporated ([@b186-btt-1-393])
  Topoisomerase I                  Irinotecan     Topoisomerase I inhibition (ClinicalTrials.gov)
  Histone deacetylase              Vorinostat     Histone deacetylase inhibitor (ClinicalTrials.gov)
  20S proteasome                   Bortezomib     dipeptidyl boronic acid inhibitor ([@b17-btt-1-393])
